High Throughput Screening Identifies a Novel Compound Protecting Cardiomyocytes from Doxorubicin-Induced Damage

Figure 4

EODB protects primary rat cardiomyocytes from DOX-induced injury. Rat primary cardiomyocytes were pretreated for 30 min with 12 μM EODB or 20 μM FeTPPs (positive control) followed by a 24 h exposure to DOX (300 ng/mL). Viability was assessed with MTT assay (a) and calcein-AM assay (b) and data were expressed as percent cytoprotection. Caspase activity was determined as a marker of apoptosis (c). Mean ± SEM of 3 independent experiments is presented. EODB provided significant () protection as compared to vehicle in all three assays.

(a)

(b)

(c)